Peptide/Protein-based Self-adjuvanted Vaccine Platform

People's research and struggle against cancer have gone through an arduous history. Scientists have spent years and a great deal of effort, from initial chemotherapy and radiotherapy to today's brilliant tumor immunotherapy. Designing vaccines using tumor antigen peptides is one of the fruits of current research. As the world's leading vaccine developer, Creative Biolabs not only has a long history of vaccine development and extensive experience in vaccine research, but also has many advanced technologies and platforms to help customers complete research tasks efficiently and with high quality.

Peptide/Protein-based Self-adjuvanted Vaccine Platform

Peptide vaccines are protective short peptides that are artificially synthesized in the amino acid sequence of the native protein. This small peptide contains only antigenic determinants. Short peptides are generally weakly immunogenic, so it is often necessary to add adjuvants to the synthesized peptide linked with a carrier to become the ideal safe vaccine. This is one of the main directions for the development of new vaccines for the prevention and control of infectious diseases and malignant tumors. These steps clearly increase the cycle, cost and production difficulties of developing such vaccines. Therefore, we designed and validated a peptide/protein vaccine platform with self-adjuvanting effects to simplify the development and production of effective peptide/protein vaccines.

In order to achieve the function of an antigenic peptide to elicit a specific immune response, in general, a peptide vaccine should comprise a cell-penetrating peptide for the delivery of an antigen, comprising multiple antigens to elicit a specific immune response, comprising an immunopotentiator with an adjuvant effect these three components. The platform we developed makes it possible to include all the necessary antiviral / antitumor components in a single vaccine. As a result, vaccines developed using the platform can induce the production of helper T cells and cytotoxic T cells, promote the production of immune memory, and the performance of the effects are not affected by the restriction of HLA. A number of studies have confirmed that the peptide vaccine developed by this platform not only has a good preventive effect on infectious diseases, but also synergizes with different immune checkpoints, and shows strong advantages in various tumor models.

Creative Biolabs' self-adjuvanting peptide vaccine platform can include all the components that can play the anti-tumor effects in a single vaccine, simplifying the process of vaccine development while ensuring the efficacy of the vaccine. A series of experimental results also confirmed the superiority of this platform. If you would like to develop a peptide or protein vaccine using our platform, please contact us immediately!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.